The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer

Summary Targeting epidermal growth factor receptor (EGFR) is an important treatment option for non-small cell lung cancer (NSCLC). These targeted therapies have been studied extensively in NSCLC in first line and subsequent lines, including maintenance in empiric fashion or in patients with tumors h...

Full description

Saved in:
Bibliographic Details
Published inJournal of infection and public health Vol. 5; pp. S50 - S60
Main Authors Al Olayan, Ashwaq, Al Hussaini, Hamad, Rahman Jazieh, Abdul
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.12.2012
Elsevier
Subjects
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - pharmacology
Carcinoma, Non-Small-Cell Lung - drug therapy
EGFR
Humans
Infectious Disease
inhibitors
Internal Medicine
lung cancer
Lung Neoplasms - drug therapy
Receptor, Epidermal Growth Factor - antagonists & inhibitors
lung cancer
inhibitors
EGFR
Online AccessGet full text

Cover

More Information
Summary:Summary Targeting epidermal growth factor receptor (EGFR) is an important treatment option for non-small cell lung cancer (NSCLC). These targeted therapies have been studied extensively in NSCLC in first line and subsequent lines, including maintenance in empiric fashion or in patients with tumors harboring the EGFR mutations. In this manuscript, we will review in details the evolutions of these targeted therapy in the management of NSCLC.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1876-0341
1876-035X
DOI:10.1016/j.jiph.2012.09.004